Biomea WKN: A3CUPH ISIN: US09077A1060 Kürzel: BMEA Forum: Aktien User: DeRitter

Biomea Fusion presented COVALENT-111 results at WCIRDC (Dec 3-6, 2025) showing durable glycemic and C‑peptide improvements with icovamenib, a selective menin inhibitor for insulin‑deficient type 2 diabetes. Data reported durable and continuous treatment effect at week 52 (9 months post last dose), exposure‑response for HbA1c, improved long‑term insulin secretion, benefit in prior GLP‑1 “failures,” and generally good tolerability with no related serious adverse events or AE‑related discontinuations. The abstract will appear in Metabolism: Experimental and Clinical and the presentation will be posted on Biomea Fusion’s investor relations site.

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor AgonistInitial Clinical Data Expected in the First Half of 2026

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

✔️

🎈

läuft gut ja -

Sehr schön 👍

📌📌📌📌

Immer wieder 😅

Sieht aus, als ob die wiederkommt...😁

Kurs hängt seit über ner halben Stunde??!!

👀👀👀